Supplementary Figure 2: Response to MDM2 inhibition and DNA damage in cells expressing exogenous wild-type or mutant p53.
From: Mutational processes shape the landscape of TP53 mutations in human cancer
a, p53WT and p53NULL A549 cells were infected with a lentivirus encoding wild-type p53, mutant p53 p.Pro278Ala, or Renilla luciferase as a negative control and treated with DMSO vehicle or nutlin-3 at 10 µM for 24 h. b–e, Immunoblots were performed on whole-cell lysate using antibodies targeting p53, p21, or β-actin and detected using HRP-conjugated secondary antibodies. Cells were seeded into the wells of 96-well dishes at 200 cells/well, treated with the indicated compounds and subjected to CellTiter-Glo assays 7 d later. Luminescence readings were normalized to those for DMSO-treated wells (100% luminescence) and wells lacking cells (0% luminescence). b, Nutlin-3, 2.5 µM. c, Nutlin-3, 5 µM. d, Etoposide, 5 µM. e, Etoposide, 5 µM. Data from 3–5 independent experiments are presented as the mean ± s.e.m. (*P < 0.05, **P < 0.01, ***P < 0.001, two-tailed paired t-test).
